array(3) { ["company_details"]=> array(13) { ["name"]=> string(26) "Bio-RAD Laboratories, Inc." ["slug"]=> string(33) "001cd-us-bio-rad-laboratories-inc" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/9d1c28c2-1b47-4093-8ed2-5151f3fe7920" ["description"]=> string(867) "Since Bio-Rad was founded 70 years ago, we have continued to provide the healthcare industry with innovative and useful products that help life science researchers accelerate the discovery process and medical diagnostic labs obtain faster, better results. Throughout our existence, we have built long-lasting customer relationships that help advance our research and development efforts in the introduction of new products and solutions. Today, Bio-Rad is a global leader, with a team of over 8,000 employees and a global network of operations that serves our life science research and clinical diagnostics customers, advancing science and saving lives, together. #Biotechnology #Biotech #STEM #Research #Biology #Chemistry #Science #PeerReviewed #Diabetes #CancerResearch #HIVResearch #Laboratory #BioRad #Cancer #DiabetesResearch #AIDSResearch #ClinicalDiagnostics" ["address_street"]=> string(20) "1000 Alfred Nobel Dr" ["address_place"]=> string(8) "Hercules" ["address_region"]=> string(10) "California" ["founding_date"]=> string(10) "1952-02-08" ["website_domain"]=> string(11) "bio-rad.com" ["website_url"]=> string(23) "https://www.bio-rad.com" ["industry_codes"]=> array(3) { [0]=> string(42) "In Vitro and In Vivo Diagnostic Substances" [1]=> string(33) "Laboratory Analytical Instruments" [2]=> string(47) "Electromedical and Electrotherapeutic Apparatus" } ["employee_count"]=> int(7900) ["article_count"]=> int(659) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(121) "S&P 500 value Bio-Rad Laboratories share: This is how much an early investment in Bio-Rad Laboratories would have yielded" ["snippet_en"]=> string(103) "If investors had invested in Bio-Rad Laboratories shares early on, they would have made so much profit." ["url"]=> string(167) "https://www.finanzen.ch/nachrichten/aktien/s-p-500-wert-bio-rad-laboratories-aktie-so-viel-haette-eine-fruehe-investition-in-bio-rad-laboratories-abgeworfen-1032620337" ["image_url"]=> string(78) "https://images.businessradar.com/articles/9f6a2e34-28ab-48f5-8c68-aad3cf187869" ["source"]=> string(11) "finanzen.ch" ["publication_date"]=> string(10) "2023-09-11" ["categories"]=> array(4) { [0]=> string(31) "Financial Update/Profit Warning" [1]=> string(12) "Stock Market" [2]=> string(14) "Issuing Shares" [3]=> string(18) "General Investment" } } [1]=> array(7) { ["title_en"]=> string(80) "HighTower Advisors LLC Sells 142 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)" ["snippet_en"]=> string(217) "HighTower Advisors LLC reduced its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 2.2% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission." ["url"]=> string(119) "http://www.defenseworld.net/2023/09/08/hightower-advisors-llc-sells-142-shares-of-bio-rad-laboratories-inc-nysebio.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/70bb08f6-8b4a-443a-8583-9cc819a13978" ["source"]=> string(16) "defenseworld.net" ["publication_date"]=> string(10) "2023-09-08" ["categories"]=> array(8) { [0]=> string(10) "Divestment" [1]=> string(24) "Stock Research & Ratings" [2]=> string(14) "Issuing Shares" [3]=> string(31) "Financial Update/Profit Warning" [4]=> string(12) "Stock Market" [5]=> string(18) "General Investment" [6]=> string(9) "Valuation" [7]=> string(24) "Quarterly/Annual Figures" } } [2]=> array(7) { ["title_en"]=> string(82) "Timothy S. Ernst Sells 2,350 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) Stock" ["snippet_en"]=> string(252) "Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Free Report) EVP Timothy S. Ernst sold 2,350 shares of the stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $395.60, for a total value of $929,660.00." ["url"]=> string(119) "http://www.defenseworld.net/2023/09/02/timothy-s-ernst-sells-2350-shares-of-bio-rad-laboratories-inc-nysebio-stock.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/dfacb159-fe6e-4a94-bd88-9bc8949d674e" ["source"]=> string(16) "defenseworld.net" ["publication_date"]=> string(10) "2023-09-02" ["categories"]=> array(5) { [0]=> string(10) "Divestment" [1]=> string(24) "Stock Research & Ratings" [2]=> string(14) "Issuing Shares" [3]=> string(12) "Stock Market" [4]=> string(24) "Quarterly/Annual Figures" } } [3]=> array(7) { ["title_en"]=> string(95) "American Century Companies Inc. Acquires 34,008 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)" ["snippet_en"]=> string(231) "American Century Companies Inc. grew its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 261.5% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission." ["url"]=> string(132) "http://www.defenseworld.net/2023/08/31/american-century-companies-inc-acquires-34008-shares-of-bio-rad-laboratories-inc-nysebio.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/6d5bd8ea-cdf3-4c11-9ab8-b487869e91d0" ["source"]=> string(16) "defenseworld.net" ["publication_date"]=> string(10) "2023-08-31" ["categories"]=> array(8) { [0]=> string(24) "Stock Research & Ratings" [1]=> string(14) "Issuing Shares" [2]=> string(31) "Financial Update/Profit Warning" [3]=> string(13) "Credit Rating" [4]=> string(24) "Quarterly/Annual Figures" [5]=> string(12) "Stock Market" [6]=> string(18) "General Investment" [7]=> string(11) "Acquisition" } } [4]=> array(7) { ["title_en"]=> string(77) "Libra Wealth LLC Acquires Shares of 445 Bio-Rad Laboratories, Inc. (NYSE:BIO)" ["snippet_en"]=> string(299) "Libra Wealth LLC bought a new position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 445 shares of the medical research company's stock," ["url"]=> string(73) "https://www.marketbeat.com/instant-alerts/nyse-bio-sec-filing-2023-07-21/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/55b9d9b8-a0e6-4b1f-96b6-eed09e498f14" ["source"]=> string(14) "marketbeat.com" ["publication_date"]=> string(10) "2023-07-21" ["categories"]=> array(6) { [0]=> string(24) "Stock Research & Ratings" [1]=> string(14) "Issuing Shares" [2]=> string(11) "Regulations" [3]=> string(31) "Financial Update/Profit Warning" [4]=> string(12) "Stock Market" [5]=> string(11) "Acquisition" } } [5]=> array(7) { ["title_en"]=> string(79) "Pacer Advisors Inc. Sells 1,042 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)" ["snippet_en"]=> string(300) "Pacer Advisors Inc. cut its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO - Get Rating) by 74.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 357 shares of the medical research company's stock after selling 1,042 shares durin" ["url"]=> string(73) "https://www.marketbeat.com/instant-alerts/nyse-bio-sec-filing-2023-05-07/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/c76a29f6-1207-4865-bb42-b0eb794c54a4" ["source"]=> string(14) "marketbeat.com" ["publication_date"]=> string(10) "2023-05-07" ["categories"]=> array(5) { [0]=> string(10) "Divestment" [1]=> string(24) "Stock Research & Ratings" [2]=> string(14) "Issuing Shares" [3]=> string(12) "Stock Market" [4]=> string(18) "General Investment" } } [6]=> array(7) { ["title_en"]=> string(50) "Notable Two Hundred Day Moving Average Cross - BIO" ["snippet_en"]=> string(276) "In trading on Thursday, shares of Bio-Rad Laboratories Inc (Symbol: BIO) crossed below their 200 day moving average of $457.73, changing hands as low as $457.20 per share. Bio-Rad Laboratories Inc shares are currently trading off about 6% on the day. The chart below shows the" ["url"]=> string(80) "https://www.nasdaq.com/articles/notable-two-hundred-day-moving-average-cross-bio" ["image_url"]=> NULL ["source"]=> string(10) "nasdaq.com" ["publication_date"]=> string(10) "2023-04-20" ["categories"]=> array(4) { [0]=> string(24) "Stock Research & Ratings" [1]=> string(10) "Relocation" [2]=> string(12) "Stock Market" [3]=> string(14) "Issuing Shares" } } [7]=> array(7) { ["title_en"]=> string(91) "102 Shares in Bio-Rad Laboratories, Inc. (NYSE:BIO) Acquired by Romano Brothers AND Company" ["snippet_en"]=> string(195) "Romano Brothers AND Company acquired a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) during the 4th quarter, according to its most recent disclosure with the SEC." ["url"]=> string(131) "https://www.defenseworld.net/2023/03/28/102-shares-in-bio-rad-laboratories-inc-nysebio-acquired-by-romano-brothers-and-company.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/2a3faf0c-facb-4a98-9f98-e436c56283b6" ["source"]=> string(16) "defenseworld.net" ["publication_date"]=> string(10) "2023-03-28" ["categories"]=> array(3) { [0]=> string(14) "Issuing Shares" [1]=> string(18) "General Investment" [2]=> string(11) "Acquisition" } } [8]=> array(7) { ["title_en"]=> string(42) "BIO Crosses Below Key Moving Average Level" ["snippet_en"]=> string(275) "In trading on Thursday, shares of Bio-Rad Laboratories Inc (Symbol: BIO) crossed below their 200 day moving average of $460.22, changing hands as low as $451.00 per share. Bio-Rad Laboratories Inc shares are currently trading down about 2.8% on the day. The chart below shows" ["url"]=> string(74) "https://www.nasdaq.com/articles/bio-crosses-below-key-moving-average-level" ["image_url"]=> NULL ["source"]=> string(10) "nasdaq.com" ["publication_date"]=> string(10) "2023-03-23" ["categories"]=> array(3) { [0]=> string(10) "Relocation" [1]=> string(12) "Stock Market" [2]=> string(14) "Issuing Shares" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(66) } [1]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(51) } [2]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(31) } [3]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(28) } [4]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(26) } [5]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(24) } [6]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(23) } [7]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(20) } [8]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(19) } [9]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(19) } [10]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(19) } [11]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(18) } [12]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(14) } [13]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(14) } [14]=> array(2) { ["name"]=> string(18) "Ecological Impacts" ["count"]=> int(13) } [15]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(13) } [16]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(9) } [17]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(9) } [18]=> array(2) { ["name"]=> string(10) "New Market" ["count"]=> int(9) } [19]=> array(2) { ["name"]=> string(11) "Regulations" ["count"]=> int(9) } [20]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(8) } [21]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(7) } [22]=> array(2) { ["name"]=> string(27) "Business Model & Innovation" ["count"]=> int(7) } [23]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(7) } [24]=> array(2) { ["name"]=> string(6) "Merger" ["count"]=> int(7) } [25]=> array(2) { ["name"]=> string(16) "Case Settlements" ["count"]=> int(6) } [26]=> array(2) { ["name"]=> string(13) "Credit Rating" ["count"]=> int(5) } [27]=> array(2) { ["name"]=> string(15) "Business Ethics" ["count"]=> int(5) } [28]=> array(2) { ["name"]=> string(25) "Business Model Resilience" ["count"]=> int(5) } [29]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(5) } } } 001cd-us-bio-rad-laboratories-inc